The announcement of promising preclinical data typically generates positive investor sentiment, especially in the biotechnology sector where the development of effective cancer treatments can significantly impact a company's valuation. The specific mention of the platform's ability to target cancer cells while preserving healthy tissue highlights a potential competitive advantage in the oncology market, which could lead to increased investor interest in INAB in the short term.